| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41afc1b11cbae48ca90470f31ef17c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aff6633139e8f79659a0587cc38a6c07 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate |
2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b100992207f3518d7dd8cc9b94d3f8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf96c9771dcd797af7a8b88bc7a93f77 |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020193621-A1 |
| titleOfInvention |
Prognostic markers, therapeutic target and treatment for acromegaly |
| abstract |
The RET/GDNF survival pathway plays an important role in acromegaly. Hence, ARF gene expression levels are predictive of a good response or resistance to first line therapy with a first-generation analogue of somatostatin. Additionally, Tyrosine Kinase Inhibitor (TKI) able to block the RET/GDNF survival pathway, in particular Sorafenib could be useful for the treatment of acromegaly resistant to first line therapy, by counteracting the survival effect of GDNF or NRTN factors, or the combination of both. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115770242-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115770242-B |
| priorityDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |